GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sensei Biotherapeutics Inc (STU:407) » Definitions » Gross-Profit-to-Asset %

Sensei Biotherapeutics (STU:407) Gross-Profit-to-Asset % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sensei Biotherapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sensei Biotherapeutics's annualized Gross Profit for the quarter that ended in Sep. 2024 was €0.00 Mil. Sensei Biotherapeutics's average Total Assets over the quarter that ended in Sep. 2024 was €51.77 Mil. Therefore, Sensei Biotherapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 0.00%.


Sensei Biotherapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Sensei Biotherapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sensei Biotherapeutics Gross-Profit-to-Asset % Chart

Sensei Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial - - - - -

Sensei Biotherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sensei Biotherapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sensei Biotherapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sensei Biotherapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sensei Biotherapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sensei Biotherapeutics's Gross-Profit-to-Asset % falls into.



Sensei Biotherapeutics Gross-Profit-to-Asset % Calculation

Sensei Biotherapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0/( (111.746+68.201)/ 2 )
=0/89.9735
=0.00 %

Sensei Biotherapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=0/( (55.553+47.982)/ 2 )
=0/51.7675
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Sensei Biotherapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sensei Biotherapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sensei Biotherapeutics Business Description

Traded in Other Exchanges
Address
1405 Research Boulevard, Suite 125, Rockville, MD, USA, 20850
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.

Sensei Biotherapeutics Headlines

No Headlines